- 93
- 0
- 约6.71千字
- 约 29页
- 2016-11-21 发布于安徽
- 举报
EGFR-TKI在肺癌一线治疗中的作用 同济医院肿瘤中心 张 莉 Contents Contents Contents 宝山壁画 宝山壁画是引人注目的昂贵文物。此壁画发现于阿鲁科尔沁旗东沙布乡境内。1994年列为“全国十大考古新发现”之一。宝山壁画中最引人注目的是《杨贵妃教鹦鹉图》。该画高0.7米、宽2.3米,用于笔重彩绘制,最突出的表现了 晚唐风格。唐代擅长绘贵妇仕女的大师周昉绘制了《杨贵妃教鹦鹉图》,不仅享誉中原,而且还影响全国各地。发现于阿旗宝山古墓里的这幅画,就是契丹人聘请中原画家按照周氏风格绘制的, 技法深得周氏画风的真传。在唐人真迹稀如星风的今天,能够从中完整了解唐代人物画的杰出成就,堪称美术史研究的辛事。这幅壁画现今保存在阿鲁科尔沁旗博物馆,历经千年,恍如新绘,是该馆的镇馆之宝。 欢迎大家观看! * * * * * * * * * * * 上世纪40年代,化疗方案的出现;90年代,含铂两联方案的确定; * * The types of patients harbouring the mutation are similar between Asian and non-Asian patients. However, it should be noted that mutations are more prevalent in Asian patients. A literature review has shown that the most common activating mutations have a similar distribution between Asian and non-Asian patients.1 This similar distribution of activating mutations suggests that EGFR-TKIs will provide benefits in Asian and non-Asian patients with these mutations. Exon 18-21 encode Gefitinib binding domain. References AstraZeneca Data on File 2009 In particular, blood based (serum/plasma) testing is particularly attractive due to the ease of accessibility to samples, but the sensitivity of the methods currently used mean that identifying EGFR mutation positive patients from blood is still challenging ? AstraZeneca research suggests that of the patients who are identified as mutation positive by analysing their tumour, approximately 50% can be identified as mutation positive by analysing circulating free DNA (cfDNA) in blood. Data demonstrated a 0% false positive rate. ? For this reason, blood based testing may not replace biopsy-based testing in the near future. However, it could be used in addition to biopsy testing, for those patients for whom the physician does not have access to a sample * * 基本治疗模式 1 EGFR-TKI用于一线治疗 2 3 基因突变检测 传统治疗模式 IB期以上的NSCLC术后行四周期化疗 2. 辅助化疗失败的患者行一线、二线化疗 3. 无法手术切除的患者行一线、二线化疗 基本治疗模式 1 EGFR-TKI用于一线治疗 2 3 基因突变检测 吉非替尼与卡铂/紫杉醇两联化疗相比用于临床选择的晚期非小细胞肺癌患者的一线治疗的随机开放III期研究(IPASS) 莫树锦,1 吴一龙,2 Sumitra Thongprasert,3 杨志新,4
原创力文档

文档评论(0)